研究業績

英文

総説

1. Yanagita M, Muto S, Nishiyama H, Ando Y, Hirata S, Doi K, Fujiwara Y, Hanafusa N, Hatta T, Hoshino J, Ichioka S, Inoue T, Ishikura K, Kato T, Kitamura H, Kobayashi Y, Koizumi Y, Kondoh C, Matsubara T, Matsubara K, Matsumoto K, Okuda Y, Okumura Y, Sakaida E, Shibagaki Y, Shimodaira H, Takano N, Uchida A, Yakushijin K, Yamamoto T, Yamamoto K, Yasuda Y, Oya M, Okada H, Nangaku M, Kashihara N． Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022． Clin Exp Nephrol, 28(2):85-122 (2024)

2. Muto S, Matsubara T, Inoue T, Kitamura H, Yamamoto K, Ishii T, Yazawa M, Yamamoto R, Okada N, Mori K, Yamada H, Kuwabara T, Yonezawa A, Fujimaru T, Kawano H, Yokoi H, Doi K, Hoshino J, Yanagita M． Chapter 1: Evaluation of kidney function in patients undergoing anticancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022． Int J Clin Oncol, 28(10):1259-1297 (2023)

3. Nishiyama H, Inoue T, Koizumi Y, Kobayashi Y, Kitamura H, Yamamoto K, Takeda T, Yamamoto T, Yamamoto R, Matsubara T, Hoshino J, Yanagita M; committee of Clinical practice guidelines for the management of kidney disease during anticancer drug therapy 2022． Chapter 2: indications and dosing of anticancer drug therapy in patients with impaired kidney function, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022． Int J Clin Oncol, 28(10):1298-1314 (2023)

​

原著論文

1. Kitahiro Y, Yamamoto K, Yakushijin K, Ioroi T, Tanda M, Itohara K, Omura T, Minami H, Yano I. The Efficacy of Bepotastine Besilate Compared With Hydroxyzine Pamoate for Preventing Infusion Reactions to the First Dose of Rituximab in Patients With Non-Hodgkin Lymphoma: Protocol for a Phase II, Double-Blind, Multicenter Randomized Trial. JMIR Res Protoc, 13: e54882 (2024)

2. Sakaue T, Yamamoto K, Itohara K, Kitahiro Y, Endo T, Yokoyama N, Ishimura T, Omura T, Yano I. Population pharmacokinetics of everolimus in renal transplant recipients receiving long-term multiple immunosuppressive therapy. Drug Metab Pharmacokinet. 56: 101009 (2024)

3. Nishiguchi H, Omura T, Sato A, Kitahiro Y, Yamamoto K, Kunimasa J, Yano I. Luteolin protects against 6-hydoroxydopamine-induced cell death via an upregulation of HRD1 and SEL1L. Neurochem Res, 49 (1): 117-128 (2024)

4. Tanda M, Yamamoto K, Hori T, Nishiguchi H, Yagi M, Shimizu M, Konishi T, Ozaki T, Yoshioka N, Tachihara M, Ito T, Ikushima S, Omura T, Yano I. Association of STAT3, CYP3A5, and ABCG2 Polymorphisms With Osimertinib-induced Adverse Events in NSCLC Patients. Anticancer Res, 43 (4): 1775-1783 (2023)

5. Mahdy WYB, Yamamoto K, Ito T, Fujiwara N, Fujioka K, Horai T, Otsuka I, Imafuku H, Omura T, Iijima K, Yano I. Physiologically-based pharmacokinetic model to investigate the effect of pregnancy on risperidone and paliperidone pharmacokinetics: Application to a pregnant woman and her neonate. Clin Transl Sci, 16 (4): 618-630 (2023)

6. Fujimoto T, Hyodo Y, Ishimura T, Tashiro Y, Endo T, Nisioka S, Yokoyama N, Yamamoto K, Yano I, Fujisawa M. Association of alpha-actinin-3 polymorphism with sarcopenia in kidney transplant recipients. Transplant Proc, 55 (4): 824-828 (2023)

7. Hori T, Yamamoto K, Ito T, Ikushima S, Omura T, Yano I. Upfront Use of First-/Second-Generation EGFR-TKI Followed by Osimertinib Shows Better Prognosis than Upfront Osimertinib Therapy in Japanese Patients with Non-small-cell Lung Cancer with Exon 19 Deletion: A Single-Center Retrospective Study. Biol Pharm Bull, 46 (6): 788-795 (2023)

8. Kurimura T, Yamamoto K, Tanaka H, Toba T, Kimura T, Habu Y, Itohara K, Kitahiro Y, Omura T, Yano I. Significance of pharmacist intervention to oral antithrombotic therapy in the pharmaceutical outpatient clinic of cardiovascular internal medicine: a retrospective cohort study. J Pharm Health Care Sci, 9 (1): 28 (2023)

9. Nakayama Y, Enomoto D, Yamamoto K, Takara K. Molecular Characteristics of Everolimus-resistant Renal Cell Carcinoma Cells Generated by Continuous Exposure to Everolimus. Anticancer Res, 43 (10): 4349-4357 (2023)

10. Tomida T, Itohara K, Yamamoto K, Kimura T, Fujita K, Uda A, Kitahiro Y, Yokoyama N, Hyodo Y, Omura T, Yano I. A model-based pharmacokinetic assessment of drug-drug interaction between tacrolimus and nirmatrelvir/ritonavir in a kidney transplant patient with COVID-19. Drug Metab Pharmacokinet, 53: 100529 (2023)

邦文

総説

1. 山本和宏．分子標的型抗がん薬による間質性肺疾患発症の分子機構に基づく予測法の開発 —mTOR阻害薬による間質性肺疾患とSTAT3の関連—．YAKUGAKU ZASSHI, 143(11): 911-916 (2023)

​

原著論文

1. 古江由依，山本和宏，木村丈司，高橋知子，川瀬愛子，清水倫子，飯田真之，松本久美子，大本暢子，山下和彦，大村友博，坂根稔康，國正淳一，矢野育子．潜在的不適切処方の中止維持における退院時薬剤情報提供の効果．医療薬学，50 (2): 75-83 (2024)

著書（分担執筆）

1. 山本和宏．14．血清補正Ca濃度の高い高リン血症のCKD患者に対して薬剤は、何を選ぶ？：100-105，39. CKD患者における緊急性の高い高カリウム血症に対して治療薬は，何を選ぶ？：261-265月刊薬事　2023年10月臨時増刊号（Vol. 65, No. 14），じほう（2023）

2. 山本和宏．透析医療をささえる人びと “たかが便秘、されど便秘”．腎不全を生きる．日本腎臓財団，68:6-19 (2023)

受賞

1. 第16回日本緩和医療薬学会学術大会 口頭発表最優秀演題賞
   飯田真之，志田有里，番匠咲帆，大本暢子，山下和彦，槇本博雄，山本和宏，大村友博，矢野育子：非がん性疼痛に対して使用されるオピオイド性鎮痛薬の薬剤師による使用状況モニタリングとその効果

2. 第6回フレッシャーズ・カンファランス 優秀演題発表賞
   高橋大，山本和宏，西口大生，糸原光太郎，北廣優実，大村友博，國正淳一，矢野育子：肺胞上皮細胞におけるエベロリムスの上皮間葉転換誘導とシグナル伝達因子の関連

3. 2023年度日本医療薬学会 JPHCS誌論文賞
   木村丈司，藤田美佐，清水倫子，住吉霞美，番匠咲帆，山本和宏，大村友博，矢野育子：Effectiveness of pharmacist intervention for deprescribing potentially inappropriate medications: a prospective observational study," J Pharm Health Care Sci, 8 (1): 12 (2022)

4. 第33回日本医療薬学会年会 優秀演題賞（International Session）
   Hori T, Yamamoto K, Ito T, Ikushima S, Itohara K, Kitahiro Y, Omura T, Yano I: Effect of early dose reduction of osimertinib on efficacy in the first-line treatment for EGFR-positive non-small cell lung cancer.